Dr. Michael Manning explores science-based management of hereditary angioedema (HAE)
Dr. Manning explains the science of HAE, some challenges you may experience with HAE patients and a specific acute treatment therapy, RUCONEST.
Dr. Manning is a board-certified allergist and immunologist practicing in Arizona. Dr. Manning has been in practice since 1989 and sees 30 to 40 HAE patients every year. He has participated in more than 70 research projects and is the lead author or co-author on numerous allergy and immunology publications, including 8 about HAE.
The Science of HAE Treatment
The Science of HAE & the Importance of C1-INH
HAE presents a variety of treatment challenges.
In this video, we will explore and examine the existing and emerging science of HAE and the importance of C1 esterase inhibitor (C1-INH). The science of HAE is a culmination of more than 20 years of scientific research.
Clinical understanding of the underlying disease process is evolving, providing a greater knowledge base on which to build individualized treatment plans.
HAE Challenges
HAE Challenges
Practitioners treating HAE encounter a variety of challenges. In this video, we'll focus on two that you may see in your practice
Redosing of acute treatment
HAE with "normal" C1 esterase inhibitor (C1-INH)
There have been no well-controlled prospective studies of C1-INH for the treatment of HAE in people with normal C1-INH lab results. The safety and efficacy of C1-INH replacement therapy in this patient population is unknown.
Pharming partnered with a world authority on the
pathogenesis and treatment of hereditary angioedema
(HAE) to develop a visualization of the interconnectedness
of the complement, contact activation, and fibrinolysis
systems and how their interworkings lead to the
symptomatology experienced in HAE attacks.
Use this visualization to explore the role of C1-INH in HAE attacks and potential HAE treatment challenges.
Redosing may prevent your patients from getting back to things that matter.
*Based on literature, 3-44% of swells needed to be retreated
Treatment with RUCONEST
Let's take a look at a specific C1-INH, RUCONEST, for HAE challenges.
RUCONEST Efficacy and Safety
Science of HAE
Hear Dr. Michael Manning talk about the science of HAE and RUCONEST
Some insurance companies are instituting new policies called accumulator adjustment programs and/or maximizer programs. These can affect your participation in the RUCONEST Patient Savings Program.
Accumulator Adjustment Programs are when your insurance plan does not apply the RUCONEST Patient Savings Program to satisfy your co-payment, deductible, or co-insurance for RUCONEST.
Co-pay Maximizer Programs are when your insurance company requires you to enroll in the RUCONEST Patient Savings Program as a condition of your plan or to waive other costs associated with the insurance plan.
If your plan has these limitations, you will not be eligible for the RUCONEST Patient Savings Program, but you may be eligible for other external needs-based assistance programs. Please contact RUCONEST SOLUTIONS for additional information.
If you have any questions, our team of experts is available to provide assistance. Our priority is your well-being. Please call RUCONEST SOLUTIONS for more information at 1-855-613-4HAE (4423).
